[A21-01] Secukinumab (psoriatic arthritis) - Addendum to Commission A20-80
Last updated 18.02.2021
Commission awarded on 12.01.2021 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Adults with active psoriatic arthritis who responded inadequately to DMARD therapy
Conclusion of dossier assessment A20-80 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.